A LITERATURE REVIEW ON ORAL HYPOGLYCEMIC DRUGS – MECHANISTIC ASPECTS
Diabetes mellitus (DM) is a worldwide rising concern that leads to an increased rate of morbidity, mortality, and health-care costs. DM is a chronic, endocrine disorder associated with hyperglycemia. The current estimated DM prevalence is over 422 million and has been progressively increasing over the past decades. Consequently, it is considered a significant problem in health-care settings. Health-care professionals who deal with such patients need to have an adequate information and drug therapy management including drugs and its regimen that are presently available in the market. This review provides an overview of potential diabetic drugs and their mechanisms. Hence, it will be proved beneficial for health-care professionals.
2. World Health Organization; Global Report on Diabetes. Available from: http://www.who.int/diabetes/global-report/en.
3. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.
4. Wang Y, Yeo QQ, Ko Y. Economic evaluations of pharmacist-managed services in people with diabetes mellitus: A systematic review. Diabet Med 2016;33:421-7.
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in Type 2 diabetes: A patient centered approach. Position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia 2012;55:1577-96.
6. Standards of medical care in diabetes-2016: Summary of revisions. Diabetes Care 2016;39 Suppl 1:S4-5.
7. Mayo Clinic Diabetes. Available from: https://www.mayoclinic.org/ diseases-conditions/diabetes/diagnosis-treatment/drc-20371451.
8. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A,Ravilla R, et al. Clinical review of antidiabetic drugs: Implications for Type 2 diabetes mellitus management. Front Endocrinol (Lausanne) 2017;8:6.
9. American Diabetes Association. (2) classification and diagnosis of diabetes. Diabetes Care 2015;38 Suppl 1:S8-16.
10. Janbon M, Chaptal J, Vedel A, Schaap J. Accidents hypoglycémiques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP). Montp Med 1942;441:21-2.
11. Bösenberg LH, van Zyl DG. The mechanism of action of oral antidiabetic drugs: A review of recent literature. J Endocrinol Metab Diabetes South Afr 2008;13:80-8.
12. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002;51 Suppl 3:S368-76.
13. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP 4th, Boyd AE 3rd, González G, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: A regulator of insulin secretion. Science 1995;268:423-6.
14. Lorenzati B, Zucco C, Miglietta S, Lamberti F, Bruno G. Oral hypoglycemic drugs: Pathophysiological basis of their mechanism of actionOral hypoglycemic drugs: Pathophysiological basis of their mechanism of action. Pharmaceuticals (Basel) 2010;3:3005-20.
15. Drugs for Type 2 diabetes. Med Lett Drugs Ther 2017;59:9-18.
16. Inzucchi SE. Oral antihyperglycemic therapy for Type 2 diabetes: Scientific review. JAMA 2002;287:360-72.
17. Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997;157:836-48.
18. Jönsson A, Rydberg T, Ekberg G, Hallengren B, Melander A. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994;17:142-5.
19. Jönsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 1998;53:429-35.
20. Tessier D, Dawson K, Tétrault JP, Bravo G, Meneilly GS. Glibenclamide vs gliclazide in Type 2 diabetes of the elderly. Diabet Med 1994;11:974 80.
21. Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of Type 2 diabetes mellitus. Drugs 1998;55:563-84.
22. DeFronzo RA. Pharmacologic therapy for Type 2 diabetes mellitus. Ann Intern Med 2000;133:73-4.
23. Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in Type 2 diabetes: A meta-analysis. Diabetes Res Clin Pract 2008;79:196-203.
24. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997;157:1681-6.
25. Chounta A, Zouridakis S, Ellinas C, Tsiodras S, Zoumpouli C, Kopanakis S, et al. Cholestatic liver injury after glimepiride therapy. J Hepatol 2005;42:944-6.
26. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr., et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-24.
27. Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, et al. Repaglinide versus nateglinide monotherapy: A randomized, multicenter study. Diabetes Care 2004;27:1265-70.
28. Novo Nordisk Pharmaceuticals: Repaglinide Product Labeling; 2003. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/020741s040lbl.pdf. [Last accessed on 2019 Oct 27].
29. Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, et al. Efficacy and safety of combination therapy: Repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003;26:2063-8.
30. Gromada J, Dissing S, Kofod H, Frøkjaer-Jensen J. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995;38:1025-32.
31. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998;47:345 51.
32. Hansen AM, Christensen IT, Hansen JB, Carr RD, Ashcroft FM, Wahl P, et al. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes 2002;51:2789 95.
33. Culy CR, Jarvis B. Repaglinide: A review of its therapeutic use in Type 2 diabetes mellitus. Drugs 2001;61:1625-60.
34. Dunn CJ, Faulds D. Nateglinide. Drugs 2000;60:607-15.
35. Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in Type 2 diabetes by nateglinide (A-4166). Diabetes Care 2001;24:1221-5.
36. Moses RG, Gomis R, Frandsen KB, Schlienger JL, Dedov I. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive Type 2 diabetes. Diabetes Care 2001;24:11-5.
37. Guardado-Mendoza R, Prioletta A, Jiménez-Ceja LM, Sosale A, Folli F. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of Type 2 diabetes mellitus. Arch Med Sci 2013;9:936-43.
38. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334:574-9.
39. Song R. Mechanism of metformin: A tale of two sites. Diabetes Care 2016;39:187-9.
40. Pollak M. Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila) 2010;3:1060-5.
41. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin study group. N Engl J Med 1995;333:541-9.
42. Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta analysis. Diabetes Care 1999;22:33-7.
43. Fogelman Y, Kitai E, Blumberg G, Golan-Cohen A, Rapoport M, Carmeli E, et al. Vitamin B12 screening in metformin-treated diabetics in primary care: Were elderly patients less likely to be tested? Aging Clin Exp Res 2017;29:135-9.
44. Moretti RM, Montagnani Marelli M, Motta M, Limonta P. Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells. Int J Cancer 2001;92:733-7.
45. Kurebayashi S, Xu X, Ishii S, Shiraishi M, Kouhara H, Kasayama S, et al. A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells. Atherosclerosis 2005;182:71 7.
46. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998;4:1046-52.
47. Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
48. Vasudevan AR, Balasubramanyam A. Thiazolidinediones: A review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004;6:850-63.
49. Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 2000;11:362-8.
50. Semple RK, Chatterjee VK, O’Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006;116:581-9.
51. Venable SJ, Aschenbrenner DS. Drug Therapy in Nursing. Hagerstown, MD: Lippincott Williams and Wilkins; 2005.
52. Food and Drug Administration. FDA Approves New Treatment for Diabetes (Press Release). Oxford: U.S. Food and Drug Administration; 2006.
53. Pathak R, Bridgeman MB. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. P T 2010;35:509-13.
54. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents? Regul Pept 2005;128:159-65.
55. Behme MT, Dupré J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in Type 1 diabetes. BMC Endocr Disord 2003;3:3.
56. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995;44:626-30.
57. Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with Type 2 diabetes: A Systematic review and meta-analysis. JAMA 2018;319:1580-91.
58. Diabetes Meds Containing Saxagliptin and Alogliptin Linked to Increased HF; 2016. Available from: https://www.pharmacypracticenews. com/Policy/Article/04-16/Diabetes Meds Containing Saxagliptin and Alogliptin-Linked-to-Increased-HF/35964/ses=ogst.
59. Abrahami D, Douros A, Yin H, Yu OH, Renoux C, Bitton A, et al. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with Type 2 diabetes: Population based cohort study. BMJ 2018;360:k872.
60. DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication May Cause Severe Joint Pain. FDA; 2015. Available from: https://www. medscape.com/viewarticle/850231. [Last accessed on 2015 Sep 10].
61. Kathe N, Shah A, Said Q, Painter JT. DPP-4 inhibitor-induced rheumatoid arthritis among diabetics: A nested case-control study. Diabetes Ther 2018;9:141-51.
62. Byetta 10 Micrograms Solution for Injection, Prefilled Pen Summary of Product Characteristics. Electronic Medicines Compendium; 2017. Available from: https://www.medicines.org.uk/emc/product/8617/ smpc.
63. Bydureon 2 mg Powder and Solvent for Prolonged-release Suspension for Injection in Pre-filled Pen Summary of Product Characteristics. Electronic Medicines Compendium; 2017. Available from: https:// www.medicines.org.uk/emc/product/3650/smpc.
64. US Food Drug Administration. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors. Available from: https://www.fda.gov/Drugs/ DrugSafety/ucm446852.htm.
65. Riser Taylor S, Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with Type 2 diabetes mellitus. Pharmacotherapy 2013;33:984-99.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.